- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | Tarsus Pharmaceuticals, Inc: Tarsus to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 09.05. | Tarsus Pharmaceuticals, Inc: Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 09.05. | Analyst Ratings For Tarsus Pharmaceuticals | 1 | Benzinga.com | ||
| 08.05. | Tarsus Pharmaceuticals GAAP EPS of -$1.01 beats by $0.18, revenue of $27.61M beats by $9.71M | 1 | Seeking Alpha | ||
| 08.05. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | 114 | GlobeNewswire (Europe) | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
| 01.05. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 | 1 | GlobeNewswire (USA) | ||
| 24.04. | BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals | 1 | Alliance News | ||
| 23.04. | Tarsus refinances existing debt with $200M financing commitment | 1 | Seeking Alpha | ||
| 23.04. | Tarsus Pharmaceuticals, Inc: Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon | 1 | GlobeNewswire (USA) | ||
| 23.04. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | Tarsus Pharmaceuticals CCO sells shares worth over $145k | 2 | Investing.com | ||
| 20.03. | Tarsus Pharmaceuticals exec sells over $135k in stock | 1 | Investing.com | ||
| 20.03. | Tarsus Pharmaceuticals CEO sells shares worth over $318k | 1 | Investing.com | ||
| 20.03. | Tarsus Pharmaceuticals executive sells over $130k in company stock | 1 | Investing.com | ||
| 12.03. | Tarsus launches a 'Mite Party' for new Xdemvy marketing campaign | 2 | FiercePharma | ||
| 06.03. | Jefferies raises Tarsus Pharma stock target to $44 on strong launch | 1 | Investing.com | ||
| 05.03. | Tarsus Pharmaceuticals, Inc: Tarsus to Participate at Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 05.03. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,316 | -7,60 % | Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? | ||
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights | Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| ASSERTIO | 1,505 | +2,38 % | Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 | ||
| ARCTURUS THERAPEUTICS | 24,030 | +4,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,700 | +0,38 % | Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark | ||
| SIGA TECHNOLOGIES | 10,520 | +5,09 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 7,400 | -1,07 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,980 | -1,88 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy positioned to be the first and only needle-free adrenaline option authorized for emergency treatment of allergic reactions (anaphylaxis) in Europe Positive CHMP opinion and recommendation... ► Artikel lesen | |
| ARVINAS | 29,650 | +0,44 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen |
Das Unternehmen TARSUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -11,44 % bei einem Aktienkurs von 25,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
